PulseTrendingJournal ClubResearchersJournalsExplore
Instagram
HomeTrendingJournal ClubExplore
Synapse
⌘+K
Synapse
June 2, 2026American Journal of Neuroradiology

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801)

View Full Paper
Ask AI
Bookmark
Share

Authors

BEB. EllingsonTCTimothy F. CloughesyXYXiaobu Ye

Discussion

Loading...

Member takes

Overview

Randomized trial shows tumor growth rate predicts survival in recurrent IDH-mutant gliomas, indicating its potential as a treatment assessment tool.

Key Points

  • The aim is to evaluate tumor growth rate (TGR) changes as a prognostic biomarker for survival in recurrent IDH-mutant gliomas treated with a PARP inhibitor.
  • Phase Ib/II clinical trial involving recurrent IDH-mutant gliomas across three cohorts.
  • Patients received pamiparib 60mg twice daily with temozolomide 20mg daily.
  • TGR assessed using serial MRI FLAIR measurements before and during treatment.
  • TGR changes were significantly associated with overall survival outcomes.
  • Growth stabilization linked to improved treatment benefits in IDH-mutant gliomas.

Cite This Study

Ellingson et al. (2026) studied this question.

synapsesocial.com/papers/6a1e726230b38c64201b5aadhttps://doi.org/10.3174/ajnr.a9438
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NCOG-32. Clinical outcomes of combination PARP inhibitor and temozolomide therapy in recurrent glioma: Insights from a single institution experience2025
  2. 2IMG-99. Volumetric tumor growth rate (TGR) modeling predicts clinical outcomes in patients with Grade 2, isocitrate dehydrogenase 1/2 mutant (mIDH1/2) glioma receiving vorasidenib or placebo in the Phase 3 INDIGO trial2025
  3. 3A phase II trial of olaparib and durvalumab in patients with recurrent IDH-mutated gliomas.2024 · 6 citations
  4. 4Phase Ib/II Study of Pamiparib Plus Radiation Therapy and/or Temozolomide in Adult Patients with Treatment-Naïve or Recurrent/Refractory Glioblastoma2025 · 6 citations
  5. 5P12.25.B A GLOBAL PHASE 3, OPEN-LABEL, RANDOMIZED-CONTROLLED STUDY FOR NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA, COMPARING NIRAPARIB VS STANDARD OF CARE TEMOZOLOMIDE TREATMENT.2025